跳转至内容
Merck
CN

D9050

N-乙酰基-2,3-脱氢-2-脱氧神经氨酸

≥93% (TLC)

别名:

2,3-脱氢-2-脱氧-N-乙酰神经氨酸

登录 查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C11H17NO8
化学文摘社编号:
分子量:
291.25
Beilstein:
8722455
EC 号:
MDL编号:
UNSPSC代码:
12352201
PubChem化学物质编号:
NACRES:
NA.25
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

synthetic (organic)

质量水平

方案

≥93% (TLC)

表单

powder

旋光性

[α]20/D 40.8 to 51.0 °, c = 0.66% (w/v) in water

颜色

white

溶解性

H2O: soluble 50 mg/mL, clear, colorless

储存温度

−20°C

SMILES字符串

CC(=O)N[C@@H]1[C@@H](O)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O

InChI

1S/C11H17NO8/c1-4(14)12-8-5(15)2-7(11(18)19)20-10(8)9(17)6(16)3-13/h2,5-6,8-10,13,15-17H,3H2,1H3,(H,12,14)(H,18,19)/t5-,6+,8+,9+,10+/m0/s1

InChI key

JINJZWSZQKHCIP-UFGQHTETSA-N

正在寻找类似产品? 访问 产品对比指南

应用

N-乙酰基-2,3-脱氢-2-脱氧神经氨酸(NADNA),一种特异性内源性神经氨酸酶(NEU)抑制剂,可用于研究内源性神经氨酸酶在发育中的作用,在神经过程和通路中的功能,以及其他依赖唾液酸化-脱唾液酸化循环的过程。

生化/生理作用

细菌、病毒和动物神经氨酸酶(唾液酸酶)的抑制剂。

其他说明

为了全面了解我们针对客户研究提供的各种单糖产品,建议您访问我们的碳水化合物分类页面。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Tejas R Karhadkar et al.
Scientific reports, 7(1), 15069-15069 (2017-11-10)
Fibrosis involves increasing amounts of scar tissue appearing in a tissue, but what drives this is unclear. In fibrotic lesions in human and mouse lungs, we found extensive desialylation of glycoconjugates, and upregulation of sialidases. The fibrosis-associated cytokine TGF-β1 upregulates
Sankar Mohan et al.
Journal of medicinal chemistry, 53(20), 7377-7391 (2010-09-30)
We report here the exploitation of the 150-cavity in the active sites of group-1 neuraminidases for the design of new triazole-containing carbocycles related to oseltamivir. Inhibition studies with virus-like particles (VLPs) containing the influenza virus neuraminidase-1 (N1) activity indicate that
Amgad Albohy et al.
Bioorganic & medicinal chemistry, 19(9), 2817-2822 (2011-04-15)
The viral neuraminidase enzyme is an established target for anti-influenza pharmaceuticals. However, viral neuraminidase inhibitors could have off-target effects due to interactions with native human neuraminidase enzymes. We report the activity of a series of known inhibitors of the influenza
Santosh Rudrawar et al.
Organic & biomolecular chemistry, 10(43), 8628-8639 (2012-09-15)
Novel 3-C-alkylated-Neu5Ac2en derivatives have been designed to target the expanded active site cavity of influenza virus sialidases with an open 150-loop, currently seen in X-ray crystal structures of influenza A virus group-1 (N1, N4, N5, N8), but not group-2 (N2
Keiko Hata et al.
Antimicrobial agents and chemotherapy, 52(10), 3484-3491 (2008-08-13)
Oseltamivir (Tamiflu) and zanamivir (Relenza), two extensively used clinically effective anti-influenza drugs, are viral sialidase (also known as neuraminidase) inhibitors that prevent the release of progeny virions and thereby limit the spread of infection. Recently mortalities and neuropsychiatric events have

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持